SCHEMBL444872

SCHEMBL444872

CS(=O)(=O)c1ccc(F)cc1

nearest known ligand 0.75

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 14/20 0.69
PTGS1 P23219 4/20 0.64
ENPP2 Q13822 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Water SCHEMBL27918427 0.97 PTGS2 (0.67) PTGS2PTGS1
SCHEMBL7395459 0.93 PTGS2 (0.74) PTGS2PTGS1
SCHEMBL6470141 0.93 PTGS2 (0.74) PTGS2PTGS1
SCHEMBL7938593 0.93 PTGS2 (0.62) PTGS2PTGS1
SCHEMBL4278822 0.89 PTGS2 (0.58) PTGS2PTGS1
SCHEMBL17439304 0.87 PTGS2 (0.64) PTGS2PTGS1
SCHEMBL7935589 0.87 PTGS2 (0.56) PTGS2PTGS1
SCHEMBL5698418 0.87 PTGS2 (0.64) PTGS2PTGS1
SCHEMBL7363510 0.87 SOS1 (0.66) PTGS2PTGS1
SCHEMBL16052791 0.87 PTGS2 (0.64) PTGS2PTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12537221-B2 Electrolyte for secondary battery and secondary battery including the same DAEGU GYEONGBUK INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2026-01-27 US claimed
CN-119944075-A Deep eutectic electrolyte based on phenylmethylsulfone and fluorine substituted derivatives thereof, preparation method thereof and lithium battery 哈尔滨工业大学(深圳)(哈尔滨工业大学深圳科技创新研究院) 2025-05-06 CN claimed
CN-118763273-A Sulfonyl deep eutectic polymer electrolyte and preparation and application thereof 青岛赛锂达储能产业技术研究院有限公司 2024-10-11 CN claimed
US-20220407116-A1 ELECTROLYTE FOR SECONDARY BATTERY AND SECONDARY BATTERY INCLUDING THE SAME DAEGU GYEONGBUK INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2022-12-22 US claimed
CN-115084655-A Electrolyte, preparation method thereof and lithium metal battery containing electrolyte 蜂巢能源科技(无锡)有限公司 2022-09-20 CN claimed
US-20150164854-A1 FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR AND USES THEROF PHARMACYCLICS LLC 2015-06-18 US claimed
WO-2013066833-A1 COMPOUNDS AND METHODS TO INHIBIT HISTONE DEACETYLASE (HDAC) ENZYMES GLAXOSMITHKLINE LLC (US) 2013-05-10 WO claimed
US-20110021528-A1 NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS PHARMACYCLICS, INC. (US) 2011-01-27 US claimed
WO-2010123507-A1 TREATMENT OF NON-LOCALIZED INFLAMMATION WITH PAN-HDAC INHIBITORS PHARMACYCLICS, INC. (US) 2010-10-28 WO claimed
US-20100236924-A1 LIQUID ELECTROLYTE COMPOSITION AND ITS USE IN GAS SENSORS LIFE SAFETY DISTRIBUTION AG (CH) 2010-09-23 US claimed
US-20040167349-A1 Novel process for preparing rac-bicalutamide and its intermediates TEVA GYOGYSZERGYAR ZARTKORUEN MUKODO RESZVENYTARSASAG (HU) 2004-08-26 US claimed
US-6737550-B2 LITHIUM SALT OF 4- FLUOROPHENYL METHYL SULFONE AS THE CHEMICAL INTERMEDIATE; DRUG WITH ANTIANDROGEN ACTIVITY BIOGAL GRYOGYSZERGYAR RT. (HU) 2004-05-18 US claimed
EP-1406855-A2 NOVEL PROCESS FOR PREPARING RAC-BICALUTAMIDE AND ITS INTERMEDIATES BIOGAL GYOGYSZERGYAR RT. (HU) 2004-04-14 EP claimed
US-20040059147-A1 Novel process for preparing rac-bicalutamide and its intermediates TEVA GYOGYSZERGYAR ZARTKORUEN MUKODO RESZVENYTARSASAG (HU) 2004-03-25 US claimed
US-20030045741-A1 Novel process for preparing rac-bicalutamide and its intermediates TEVA GYOGYSZERGYAR ZARTKORUEN MUKODO RESZVENYTARSASAG (HU) 2003-03-06 US claimed
WO-2002100339-A2 NOVEL PROCESS FOR PREPARING RAC-BICALUTAMIDE AND ITS INTERMEDIATES BIOGAL GYOGYSZERGYAR RT. (HU) 2002-12-19 WO claimed
US-5897940-A Ink jet transparencies XEROX CORPORATION (US) 1999-04-27 US claimed
US-5744273-A Laminatable backing substrates containing fluoro compounds for improved toner flow XEROX CORPORATION (US) 1998-04-28 US claimed
US-4921941-A TRIPEPTIDE ESTERS SCHERING CORPORATION (US) 1990-05-01 US claimed
WO-1989000165-A1 ORALLY ACTIVE ANTIANDROGENS SCHERING CORPORATION (US) 1989-01-12 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040059147-A1 Novel process for preparing rac-bicalutamide and its intermediates RAC2, RAC3, RAC1 PTGS2 2447/4885PTGS1 2713/4885ENPP2 1538/4885
US-20150164854-A1 FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR AND USES THEROF HDAC1, HDAC2, HDAC8 PTGS2 4003/4885PTGS1 4117/4885ENPP2 3338/4885
US-12537221-B2 Electrolyte for secondary battery and secondary battery including the same NCS1, KCNN2, SLC9A1 PTGS2 4197/4885PTGS1 4138/4885ENPP2 4847/4885
US-20030045741-A1 Novel process for preparing rac-bicalutamide and its intermediates RAC2, RAC3, RAC1 PTGS2 2447/4885PTGS1 2713/4885ENPP2 1538/4885
US-20110021528-A1 NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS HDAC1, HDAC3, HDAC5 PTGS2 2220/4885PTGS1 1439/4885ENPP2 1117/4885
US-20040167349-A1 Novel process for preparing rac-bicalutamide and its intermediates RAC2, RAC3, RAC1 PTGS2 2447/4885PTGS1 2713/4885ENPP2 1538/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.